BNP Paribas Financial Markets
KRYS icon

BNP Paribas Financial Markets’s Krystal Biotech KRYS Stock Holding History

BNP Paribas Financial Markets’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24M Buy
93,031
+39,120
+73% +$10.4M 0.01% 1036
2025
Q4 		$13.3M Buy
53,911
+44,732
+487% +$9.41M 0.01% 1427
2025
Q3 		$1.62M Buy
9,179
+1,996
+28% +$299K ﹤0.01% 2769
2025
Q2 		$987K Buy
7,183
+2,746
+62% +$403K ﹤0.01% 2917
2025
Q1 		$800K Sell
4,437
-3,352
-43% -$564K ﹤0.01% 2923
2024
Q4 		$1.22M Sell
7,789
-2,644
-25% -$469K ﹤0.01% 2691
2024
Q3 		$1.9M Buy
10,433
+8,098
+347% +$1.56M ﹤0.01% 2076
2024
Q2 		$429K Sell
2,335
-14,443
-86% -$2.42M ﹤0.01% 2746
2024
Q1 		$2.99M Sell
16,778
-22,294
-57% -$3.1M ﹤0.01% 1807
2023
Q4 		$4.85M Buy
39,072
+10,057
+35% +$1.12M 0.01% 1423
2023
Q3 		$3.37M Buy
29,015
+13,983
+93% +$1.71M ﹤0.01% 1545
2023
Q2 		$1.76M Sell
15,032
-10,379
-41% -$1.06M ﹤0.01% 1830
2023
Q1 		$2.03M Buy
25,411
+12,607
+98% +$990K ﹤0.01% 1796
2022
Q4 		$1.01M Sell
12,804
-9,076
-41% -$674K ﹤0.01% 2153
2022
Q3 		$1.53M Buy
21,880
+17,303
+378% +$1.25M ﹤0.01% 2165
2022
Q2 		$301K Buy
4,577
+2,236
+96% +$139K ﹤0.01% 2913
2022
Q1 		$156K Sell
2,341
-3,145
-57% -$196K ﹤0.01% 3209
2021
Q4 		$384K Buy
5,486
+1,557
+40% +$90.6K ﹤0.01% 3141
2021
Q3 		$205K Buy
3,929
+3,202
+440% +$190K ﹤0.01% 3029
2021
Q2 		$49.4K Sell
727
-1,210
-62% -$84.5K ﹤0.01% 3263
2021
Q1 		$149K Buy
1,937
+20
+1% +$1.45K ﹤0.01% 3174
2020
Q4 		$115K Sell
1,917
-1,306
-41% -$65.2K ﹤0.01% 3144
2020
Q3 		$139K Buy
3,223
+1,675
+108% +$72.7K ﹤0.01% 2937
2020
Q2 		$64.1K Sell
1,548
-3,929
-72% -$189K ﹤0.01% 2941
2020
Q1 		$237K Buy
5,477
+4,248
+346% +$222K ﹤0.01% 2773
2019
Q4 		$68.1K Sell
1,229
-89
-7% -$4.37K ﹤0.01% 3493
2019
Q3 		$45.8K Buy
1,318
+1,263
+2,296% +$56.5K ﹤0.01% 3528
2019
Q2 		$2.21K Buy
+55
New +$1.8K ﹤0.01% 4311

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BNP Paribas Financial Markets's KRYS Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Krystal Biotech (KRYS) stake by 73% in Q1 2026, buying an estimated $10.4M and bringing the position to 93,031 shares worth $24M. The position accounts for 0.01% of the portfolio, ranked #1036.

BNP Paribas Financial Markets first reported a position in KRYS in Q2 2019 and has held it in 28 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • BNP Paribas Financial Markets held 93,031 shares of Krystal Biotech worth $24M as of Q1 2026.
  • BNP Paribas Financial Markets bought 39,120 Krystal Biotech shares in Q1 2026, an estimated $10.4M.
  • Krystal Biotech made up 0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #1036 holding.
  • BNP Paribas Financial Markets first reported a position in Krystal Biotech in Q2 2019 and has held it in 28 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.